xi Notable Changes to 2019 Nelson’s Pediatric Antimicrobial Therapy, 25th Edition Nelson’s Pediatric Antimicrobial Therapy has been updated to incorporate new approaches to treatment based on clinical guidelines and new publications, as well as to be consistent with Red Book: 2018–2021 Report of the Committee on Infectious Diseases, 31st Edition. Color has been added throughout to improve navigation and help you find the best treatment options quickly. Antimicrobials, Antifungals, Antivirals, and Antiparasitics Updates to tables for susceptibility of bacterial, fungal, viral, and parasitic pathogens. Tables are now color coded to make it easier to instantly find the best treatment options by pathogen. Presents new safety data on fluoroquinolones (including moxifloxacin) in children, supporting current policy that these drugs are appropriate for situations in which no other drug is active against the bacterial pathogen. Updates for doxycycline dosing, which has been converted to kilogram-based dosing to be consistent with US Food and Drug Administration (FDA) package label dosing. Provides extensive explanations of the new beta-lactam/beta-lactamase inhibitor combinations. At least 4 new antibiotics are under investigation in children, mostly for multidrug-resistant Gram-negative bacilli. Specific, new, and evolving recommenda- tions about antifungal therapeutic drug levels for several invasive fungal infections are clarified, particularly in immunocompromised children. Adds Candida auris as a newly emergent fungal pathogen. Incorporates new coccidioidomycosis guidelines to updated recommendations. Includes new approaches to mucormycosis, a devastating infection, based on published data, animal models, and the extensive experience of William J. Steinbach, MD. Reorganizes antiviral table into 2 tables for easier reading: common viral pathogens are in one table, and HIV, hepatitis B, and hepatitis C are in a second table. Updates to babesiosis to include a recent publication supporting the choice of azithro- mycin and atovaquone for both mild to moderate and severe infection. Updates, including new information on drug therapy and steroid therapy, for neuro- cysticercosis incorporating the Infectious Diseases Society of America (IDSA) and American Society of Tropical Medicine and Hygiene guidelines. Updates for Giardia, including tinidazole and nitazoxanide as drugs of choice, based on the IDSA guidelines for clinical management of diarrhea. ch00-Nelson-2019_FM_i-xii.indd 11 11/12/18 2:51 PM
Previous Page Next Page